Carbamazepine in Reiter's syndrome

Editor,—A psoriatic spectrum with Reiter's syndrome as the most severe manifestation occurs with greater frequency in HIV infected individuals. Immunosuppressive therapies for RS are associated with a poor response and increased morbidity. We describe a case where carbamazepine showed an excellent response in an HIV infected patient with Reiter's syndrome.

A 30 year old married man presented with erythematous papules and plaques of 2 months' duration covered with hard limpet-like scales on face, body, and both extremities (fig 1). Pain and stiffness showed keratoderma blennorrhagica and subungual hyperkeratosis with distal onycholysis. Both knees and wrists had painful swelling with restriction of movements. With this clinical presentation Reiter's syndrome was inferred. All routine investigations were normal except a raised erythrocyte sedimentation rate of 100 mm in the first hour. x Rays of the affected joints were normal. ELISA for HIV-1 and HIV-2 was positive with two kits (Immunocomb, Tri-dot) and confirmed with western blotting technique (Speciality Ranbaxy Limited). The absolute helper T lymphocyte count was 435 cells ×10⁹/l. Human leucocyte antigen B27 and rheumatoid factor were negative. The patient was commenced on prednisolone by mouth 60 mg daily and indomethacin by mouth 25 mg three times daily without any concomitant side effects. A rapid clearing of erythema, secondary to raised levels of neuropeptides, with carbamazepine may have been mediated through inhibition of these neuropeptides and by inhibition of uptake of noradrenaline. The exacerbation and subsequent resolution of lesions on withdrawal and reinstitution of carbamazepine respectively proves its efficacy in our patient. Also, the clinical remission maintained for 1 year after stopping carbamazepine was further evidence of its therapeutic role in Reiter's syndrome. The therapeutic response seen in our patient conforms to that seen in the HIV-1 positive patient of Smith et al. This apparent success adds carbamazepine to the armamentarium against Reiter's syndrome in an HIV infected patient. This is the first reported case and an evaluation of long term carbamazepine therapy is warranted.

N N GOYAL
R S DHURAT
H R JERAJANI
Department of Dermatology, LTM Medical College and LTM General Hospital, Nagoa, Mumbai - 400066, India

Correspondence to: Dr N N Goyal, 14 Vinay, Prayas Sadan, Chheda nagar, Chemburb, Mumbai - 400089, India

madhanil@hotmail.com


Accepted for publication 20 March 2000

Condoms and warts

Editor,—Wen et al1 should be applauded for their attempt to address the key question of whether or not condoms protect people from genital warts. However, some of the major study variables need clarifying, as they did not match up with my knowledge of the Sydney Sexual Health Centre (SSHC) database. The article discussed the issue of “acquisition of genital warts” and was presented as an incidence study. Cases were defined as: “All patients with a new diagnosis of macroscopic genital warts who attended SSHC [in] 1996.” However, many of these patients had been previously diagnosed with genital warts elsewhere while others had recurrent lesions. In Australia, most genital warts are managed by general practitioners.2 Consequently, the experience of specialist services is biased towards recurrent and difficult cases. “New diagnosis” in this situation means new to the clinic but not necessarily new to the patient. This means that the main outcome measure was a mixture of incident, prevalent, and recurrent cases, with the possibility that the warts may have affected the behaviour of many of the study subjects.

The SSHC database does document whether a person has previously been diagnosed with HPV infection. To me, the study would have had more validity if patients with a previous history had been reclassified.

The diagnostic grouping for warts at SSHC does not distinguish between genital and anal lesions. The readers of the journal need to know that many of these male “genital” wart cases would have been homosexually active men with anal warts. This is important as risk factors for penile and anal warts may differ, potentially confusing the results of the present study.

Originally developed as an HIV risk measure, the condom use variable at SSHC only refers to the previous 3 months or since the last registration/disease episode. Wen et al’s article failed to mention that this variable was time limited. As 3 months is the median duration before the appearance of exophytic warts,1 up to half of the relevant sexual behaviour may have been overlooked.

Finally, the referent group in the table describing condom use deemed as “Not applicable, no sex” should have been more accurately described as “No vaginal or anal sex in the previous 3 months.” Many of these people would have practised oral sex or other sexual acts during those 3 months. Others may have ceased practising vaginal or anal intercourse up to 3 months earlier because of their persistent or recurrent warts.

Large relational quality assured clinical databases can be powerful tools for health service evaluation, surveillance, and the generation of research questions. It may be prudent for researchers to engage the people responsible for designing and maintaining those databases to minimise errors of interpretation.

LINDA DAYAN
Sydney Sexual Health Centre and Sexual Health Services, Northern Sydney Health, Sydney, Australia
LDayan@doh.health.nsw.gov.au


Accepted for publication 20 March 2000

Reply

Editor,—We are grateful to Dr Dayan for her helpful and constructive comments. The major criticism of our paper relates to the selection of cases, and the possible inclusion...
Photosensitivity reaction to efavirenz

EDITOR,—The non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz is a recent addition to the armamentarium available to physicians in the treatment of HIV infection. However, at present the known side effect profile of this new agent is still in its infancy. We would like to report a case of photosensitivity associated with efavirenz. A 27 year old white homosexual man was commenced on combivir (zidovudine/ lamivudine) and efavirenz in June 1997. In March of 1998 his viral load was 356 790 copies/ml and his CD 4 count was 512 cells/l, he was commenced on dual antiretroviral therapy. (French). 


HIV associated cytomegalovirus retinitis in Melbourne, Australia

EDITOR,—We report the results of a 12 year review of human immunodeficiency virus (HIV) associated cytomegalovirus (CMV) retinitis in Melbourne, Australia.

We conducted a retrospective review of all HIV infected patients diagnosed with CMV retinitis at Fairfield Hospital and the Alfred Hospital between 1984 and 1996, aiming to identify factors at diagnosis of CMV retinitis which were predictive of outcome. Both hospitals had the same protocol for the treatment of CMV retinitis and employed 3 monthly ophthalmological screening of all HIV infected patients with CD4 counts of less than 50 x10^9/l.

The study outcomes were visual loss and death. Moderate visual loss was defined as visual acuity of less than 6/12 in the better eye, and severe visual loss was visual acuity of less than 6/60 in the better eye (this is legal blindness in Australia). CMV retinitis was diagnosed in 212 of 1281 patients (16.5%) with AIDS over the study period. As of June 1998, 193 (93%) had died, at a median time of 36 weeks (range 192) from CMV diagnosis. Seventy four patients (35%) developed moderate visual loss at a median time of 23 weeks (range 0–163) and 30 patients (14%) developed severe visual loss at a median time of 35 weeks (range 0–120) from diagnosis of CMV retinitis.

The presence of visual symptoms at diagnosis of CMV retinitis was predictive of the development of moderate visual loss (relative risk 2.1, 95% confidence interval 1.1–4.2). Fifty eight of 138 patients (42%) with visual symptoms at diagnosis developed moderate visual loss, compared with 16 of 64 patients (25%) who were asymptomatic at diagnosis (p=0.02). The presence of visual symptoms at diagnosis was not predictive of the development of severe visual loss, or early death (p>0.2). Other factors measured at diagnosis of CMV retinitis included the patients’ age, CD4 count, weight, visual acuity, and the presence of any previous AIDS defining condition. None of these was associated with the development of visual loss or early death (p>0.1).

The advent of highly active antiretroviral therapy (HAART) has resulted in a reduction in the incidence of new diagnoses of opportunistic infections. Prolonged survival times with CMV retinitis have been demonstrated in patients who achieve immunological recovery with HAART. The ability to predict those patients who are at highest risk of visual loss may assist in advising those who may reasonably cease maintenance therapy for CMV retinitis following immune restoration.

An understanding of the natural history of CMV retinitis in the pre-HAART years remains important in managing patients who are failing HIV therapy.

The only factor measurable at diagnosis of CMV retinitis that was predictive of outcome was the presence of visual symptoms. The use of routine ophthalmological screening in HIV infected individuals with low CD4 counts aims to detect CMV retinitis before visual symptoms occur. It is possible that visual loss may be prevented by detecting disease before retinal damage occurs. A prospective evaluation is needed to confirm this finding.

C L CHERRY
A M MJICH
J FI HOY
Department of Infectious Diseases, The Alfred Hospital, Victoria, Australia

A J H HALL
Department of Ophthalmology, The Alfred Hospital, Victoria, Australia

M E HELLARD
Department of Infectious Diseases, The Alfred Hospital, Victoria, Australia and Department of Epidemiology and Preventive Medicine, Monash University, Victoria, Australia

M BRYANT
B DEGRAAFF
Department of Infectious Diseases, The Alfred Hospital, Victoria, Australia

C K FAIRLEY
Department of Infectious Diseases, The Alfred Hospital, Victoria, Australia and Department of Epidemiology and Preventive Medicine, Monash University, Victoria, Australia. Correspondence to Catherine Cherry, The Alfred Hospital, Commercial Rd, Prahran 3181, Victoria, Australia katie@netspace.net.au


Azithromycin vs oxytetracycline for the treatment of non-specific urethritis

Editor,—Single dose azithromycin 1 g rather than multidose tetracyclines or oxytetracycline over several days for the treatment of chlamydial urethritis is becoming more widespread as patient acceptability and improved compliance outweigh cost considerations. However, in men, treatment is often initiated on the basis of evidence of urethritis before the chlamydial result is available. Recently, a number of reports have studied the efficacy of azithromycin in the treatment of non-gonococcal non-chlamydial urethritis (NSU), but recently published evidence-based guidelines for the management of NSU recommend either doxycycline 100 mg twice daily for 7 days or azithromycin 1 g immediately.

In this genitourinary medicine clinic azithromycin became first-line treatment for all proved or suspected chlamydial infections from 1 April 1998. This retrospective study assessed the efficacy of azithromycin for the treatment of NSU compared with oxytetracycline 250 mg four times daily for 7 days, the previous first-line treatment regimen for men with microscopic urethritis in whom no Gram negative diplococci were observed.

NSU was defined as the presence of at least five polymorphonuclear leukocytes (PMNL) in five or more fields of microscopy of a urethral smear, negative culture of Neisseria gonorrhoea after direct plating onto modified New York culture medium and negative chlamydial screen on ELISA testing (Syva) of a urethral swab.

The results (see table 1) demonstrate that azithromycin is as effective as oxytetracycline in curing NSU, and produces fewer side effects than oxytetracycline.

Table 1. Comparative age, symptoms, and response to treatment of the two groups.

<table>
<thead>
<tr>
<th>Group</th>
<th>Number treated</th>
<th>Median age</th>
<th>No treated (%)</th>
<th>No treatment (%)</th>
<th>Outcomes uncertain (%)</th>
<th>Symptomatic</th>
<th>Asymptomatic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxytetracycline</td>
<td>76</td>
<td>28 (16-83)</td>
<td>25 (16-54)</td>
<td>25 (48)</td>
<td>35 (46)</td>
<td>27 (32)</td>
<td>27 (28)</td>
</tr>
<tr>
<td>Azithromycin</td>
<td>52</td>
<td>29 (30)</td>
<td>27 (52)</td>
<td>6 (8)</td>
<td>0</td>
<td>9 (16)</td>
<td>8 (16)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcome</th>
<th>No of patients</th>
<th>All treated (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptomatic</td>
<td>68</td>
<td>80</td>
</tr>
<tr>
<td>Asymptomatic</td>
<td>73</td>
<td>80</td>
</tr>
</tbody>
</table>

The results of the two glass urine test did not differ significantly between the two groups but overall was positive in 70% of symptomatic patients compared with only 47% asymptomatic (p<0.01). Its low sensitivity and specificity are likely to be even lower in asymptomatic patients. Default from follow up occurred more frequently in the asymptomatic patients, but was less evident in the azithromycin treated group, who had a lower default rate overall, as previously reported.

In conclusion, although the numbers are small, it would appear that azithromycin is an effective treatment for NSU, and can be given at the time of initial diagnosis, pending the chlamydial result. Financial considerations preclude the use of azithromycin as first-line treatment for NSU in many centres, but better compliance resulting in fewer treatment failures, and fewer wasted appointments from defaults may counter the economic argument.

C Thompson
Ffji Acute Hospitals NHS Trust, Victoria Hospital, Kirkcaldy, Ffji, KY2 5AH

Many elderly people maintain heterosexual and homosexual activity. Therefore this age group is at a risk of all sexually transmitted infections. In our study, a smaller percentage of older attendees had STIs compared with previous studies. However, the number of older patients who attended for non-STI management is comparable. The delay between symptom recognition and healthcare presentation is a feature of STI related illness behaviour. The delay behaviour among individuals with suspected STIs is age specific, with longer latency periods experienced by people over the age of 50. This finding was seen in our study as well.

Nelson David
Sasikala Rajamanoharan
Alan Tang
Department of GU Medicine, Royal Berkshire Hospital, Reading RG1 5AH

Correspondence to: Dr Nelson David


Accepted for publication 30 April 2000

Tertiary syphilis

Editor,—I read Dr Reed’s letter on tertiary syphilis with interest.

The regimen he describes for the treatment of early syphilis—arsenic, bismuth, and round the clock aqueous penicillin, was used in our hospital from 1946–8 although daily penicillin in beaswax was also used. It was unclear how much inactive penicillin K was in the commercial product used. The penicillin given here was higher than that in Lincoln (40 000–75 000 units 3–4 hourly).

There were 10 treatment failures (reinfections) out of 215 patients described.

Treponema pallidum remains viable in the CSF even after adequate clinical treatment.
The old adage that we achieve clinical but not microbiological cure of syphilis with antibiotics is probably true.

It is likely that most people in developed countries nowadays who have untreated syphilis have received treponemoidal antibiotics for other intercurrent infections, so that any neurosyphilis that developed would either be modified with few physical signs or would be completely treated and clinically cured. However, others disagree with this. By the question Dr Reed asks, we haven’t seen anyone treated since the second world war who has developed neurosyphilis in subsequent years.

DAVID GOLDMEIER

1 Reed TAG. Tertiary syphilis. Sex Transm Inf 1999;75:75.


I was delighted when the editor sent me this book and asked me to review it. I had looked forward with anticipation to the original series that were published in the BMJ. I had thought then that each article was just superb and now they are all neatly packed together in this ABC. I am of the opinion that this is an excellent book which achieves its aim completely. On the cover, it says “it is an ideal reference for doctors, nurses, students and all those not involved in the area of sexual health,” and Professor Adler adds in the foreword that this book will put the profession in touch with the real world, real people, with real problems, and fill a large gap in our knowledge.

John Tomlinson, the editor, has pulled together an excellent group of experts who have practical experience in the field and have managed to condense that experience into a series of short articles, all of which make informative, yet entertaining reading. In my opinion, no specific background is required to gain information from these articles and I have recommended specific sections of this ABC to individuals who need to read about their problem.

Those of us who work in sexual medicine were amused that the BMJ had to carry a warning about the sexually explicit material inside and, indeed, John Tomlinson refers to this in the preface and admits that a very small number of readers were offended.

Sexual health is an essential part of having a happy and fulfilling life, and everyone who works in a caring profession should be comfortable when the conversation drifts into areas of sexuality. Patients, who often broach the topic with trepidation, need to be assured of a sensitive hearing. In my opinion, this excellent book will give anyone in the caring profession a good grounding in sexual matters, so that they can explore these areas with patients with less embarrassment and have some idea of likely strategies of management.

COLM O’MAHONY

NOTICES

International Herpes Alliance and International Herpes Management Forum

The International Herpes Alliance has introduced a website (www.herpesalliance.org) from which can be downloaded patient information leaflets. Its sister organisation the International Herpes Management Forum (website: www.IHMF.org) has launched new guidelines on the management of herpesvirus infections in pregnancy at the 9th International Congress on Infectious Disease (ICID) in Buenos Aires.

Pan-American Health Organization, regional office of the World Health Organization

A catalogue of publications is available online (www.paho.org). The monthly journal of PAHO, the Pan American Journal of Public Health, is also available (subscriptions: pubsvc@tsp.sheridan.com).

Imperial College School of Medicine, Division of Paediatrics, Obstetrics, and Gynaecology, Advanced Course for Obstetricians and Gynaecologists, 19–23 June 2000

Further details: Symposium Office, Imperial College School of Medicine, Queen Charlotte’s and Chelsea Hospital, Goldhawk Road, London W6 0XG (tel: 020 8383 3904; fax: 020 8383 8555; email: sympreg@ac.ca.uk).

Australasian Sexual Health Conference, Ven Troppo, Carlton Hotel, Darwin, Northern Territory, 21–24 June 2000

Further details: Shirley Corley, Conference manager, Dart Associates, PO Box 781, Lane Cove, 2066 NSW, Australia (tel: 02 9418 9396/97; fax: 02 9418 9398; email: dartcon@mpx.com.au).

Imperial College School of Medicine, Division of Paediatrics, Obstetrics, and Gynaecology, Caring for Sexuality in Health and Illness (for healthcare professionals and nurses), jointly with Association of Psychosexual Nursing 27 June 2000

Further details: Symposium Office, Imperial College School of Medicine, Queen Charlotte’s and Chelsea Hospital, Goldhawk Road, London W6 OXG (tel: 020 8383 3904; fax: 020 8383 8555; email: sympreg@ac.ca.uk).

Downloaded from http://sti.bmj.com/ on June 16, 2017 - Published by group.bmj.com
Sexual Health and HIV Conference: Facing the Millennium, Portsmouth Marriott Hotel, Portsmouth, 28 June 2000
Further details: Rebecca Mitchell (tel: 023 9286 6796; fax: 023 9286 6796).

6th ESC Congress on Contraception in the Third Millennium: a (R)Evolution in Reproductive and Sexual Health, Ljubljana, Slovenia, 28 June–1 July 2000
Further details: Orga-Med Congress Office, Mr Peter Ezard, Eissenestraat 77, B-1740 Ternat, Belgium (tel: +32 2 582 08 52; fax: +32 2 582 55 15; email: orgamed@village.uunet.be).

Imperial College School of Medicine, Division of Paediatrics, Obstetrics, and Gynaecology, Bereavement, 5 July 2000
Further details: Symposium Office, Imperial College School of Medicine, Queen Charlotte’s and Chelsea Hospital, Goldhawk Road, London W6 0XG (tel: 020 8383 3904; fax: 020 8383 8555; email: sympreg@ic.ac.uk).

Imperial College School of Medicine, Division of Paediatrics, Obstetrics, and Gynaecology, New Horizons in Recurrent Pregnancy Loss, 29 June–1 July 2000
Further details: Symposium Office, Imperial College School of Medicine, Queen Charlotte’s and Chelsea Hospital, Goldhawk Road, London W6 0XG (tel: 020 8383 3904; fax: 020 8383 8555; email: sympreg@ic.ac.uk).

Imperial College School of Medicine, Division of Paediatrics, Obstetrics, and Gynaecology, Advances in Obstetric Medicine: International Meeting of Obstetric Medicine Societies (satellite to ISSHP, Paris, 6–7 July 2000
Further details: Symposium Office, Imperial College School of Medicine, Queen Charlotte’s and Chelsea Hospital, Goldhawk Road, London W6 0XG (tel: 020 8383 3904; fax: 020 8383 8555; email: sympreg@ic.ac.uk).

XIII International AIDS Conference, 9–14 July 2000, Durban, South Africa
Further details: Congrex Sweden AB, PO Box 5619, Linnegatan 89A, 114 86 Stockholm, Sweden (tel: +46 8 459 6600; fax: +46 8 661 91 25; email: aids2000@congrex.se).


Ethical Issues in International Health Research, Durban, South Africa, 16–21 July 2000 (immediately following XIII International AIDS Conference)
Further details: Marie-Christine Ryckaert, Program director, Ethical Issues in International Health Research, Harvard University, John F Kennedy School of Government, Cambridge, MA 02138, USA (tel: (617) 496-0484 ex 7474; fax: (617) 495-3090; email: Marie-Christine.Ryckaert@harvard.edu).

Further details: PACIFICO, SA, E Granados, 44, 08008 Barcelona, Spain (tel: +34.93.454.54.00; fax: +34.93.451.74.38; email: gp@pacifico-meetings.com).

MSSVD Clinical Developments Fund
The MSSVD Clinical Developments Fund is asking for applications for funding to support projects that advance the understanding and practice of genitourinary medicine. An amount of £10 000 is available to one or more successful applicant(s). Closing date for application is 25 August 2000. Further details: Dr Keith Radcliffe, Honorary Assistant Secretary MSSVD, Whitall Street Clinic, Whitall Street, Birmingham B4 6DH (tel: 0121 237 5719; fax: 0121 237 5729; email: keith.radcliffe@bscht.wmids.nhs.uk).

3rd Congress of the Baltic Association of Dermatovenerology, 7–9 September 2000, Riga, Latvia
Further details: Professor Andris Y Rubins, Department of Dermatovenerology, Medical Academy of Latvia, K Valdemara Street, 76–75, Riga, LV-1013, Latvia (tel: +(371) 7370395; fax: +(371) 7361615; email: arubins@apollo.lv).

National NCCG Update Meeting, Bromsgrove Stakis Hotel, 23–24 September 2000
Further details: Kathy Taylor (tel: 01384 235207; email: palmartraining@tesco.net).

11th Regional Meeting of International Union against Sexually Transmitted Infections, South East Asian and Western Pacific Branch and 24th National Conference of Indian Association for the Study of Sexually Transmitted Diseases and AIDS, 13–15 October 2000, Chandigarh, India
Further details: Dr Bhushan Kumar, Organising Secretary, 11th Regional Meeting of IUSTTI–Asia Pacific (SE Asia and W Pacific Branch), Department of Dermatology, Venerology and Leprosy, PGIMER, Chandigarh - 160 012, India (tel: +91 (0172) 745330; fax: +91 (0172) 744401/745078; email: kumarbhushan@hotmail.com).

Consortium of Thai Training Institutes for STDs and AIDS—10th STDs/AIDS diploma course, Bangkok Hospital, Bangkok (30 Oct–12 Nov) and Prince of Songkla University, Hat Yai, Thailand (13–23 Nov) 30 October–23 November 2000
Further details: Hat Yai Secretariat, Dr Veerapol Chandeying, Dept of OB-GYN, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkla 90110, Thailand (fax: (66-74) 446 361; email: cverapol@ratree.psu.ac.th or Bangkok Secretariat, Dr Thaniat Palanuvej, Bangkok Hospital, 189 Sathorn Road, Bangkok 10120, Thailand (fax: (66-2) 286 3013; email: pthanit@email.ksc.net).

Consortium of Thai Training Institutes for STDs and AIDS—International Reunion and Refreshers Course on Sexual Health, Lee Garden Plaza Hotel, Hat Yai, Thailand 24–26 November 2000
Further details: Hat Yai Secretariat, Dr Veerapol Chandeying, Dept of OB-GYN, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkla 90110, Thailand (fax: (66-74) 446 361; email: cverapol@ratree.psu.ac.th or Bangkok Secretariat, Dr Thaniat Palanuvej, Bangkok Hospital, 189 Sathorn Road, Bangkok 10120, Thailand (fax: (66-2) 286 3013; email: pthanit@email.ksc.net).

CORRECTION
CURRENT PUBLICATIONS

Selected titles from recent reports published worldwide are arranged in the following sections:

Gonorrhoea
Chlamydia
Candidiasis
Bacterial vaginosis
Trichomoniasis
Pelvic inflammatory disease
Syphilis and other treponematoses
Hepatitis
Herpes
Human papillomavirus infection
Other sexually transmitted infections
Human papillomavirus infection
Herpes
Hepatitis
Syphilis and other treponematoses
Pelvic inflammatory disease
Bacterial vaginosis
Candidiasis
Gonorrhoea
Following sections:

Susceptibility to gonococcal infection during the menstrual cycle.
S NOWICKI, A HARTVANTASSELL, B NOWICKI. JAMA 2000;283:1291

‘Broken windows’ and the risk of gonorrhoea.

LV TORIAN, HA MAKKI, IB MENZIES et al. AIDS 2000;14:189–96

Rise in gonorrhoea in London, UK.
IMC MARTIN, CA ISON. Lancet 2000;355:623

Urine screening for gonococcal and chlamydial infections at community-based organizations in a high-morbidity area.
CA JONES, RC KNAUP, M HAYES, BP STONER. Sex Transm Dis 2000;27:146–51

Evaluation of four commercial transport media for the survival of Neisseria gonorrhoeae.


Prevalence and tetM subtype of tetracycline-resistant Neisseria gonorrhoeae in Ohio, 1994.
DL TREES, Y FAEKE, SW NEAL, JS KNAUP. Sex Transm Dis 2000;27:46–8

GM LI, Q CHEN, SC WANG. Sex Transm Dis 2000;27:115–8

Effects of the immunoglobulin A1 protease on Neisseria gonorrhoeae trafficking across polarized T84 epithelial monolayers.

Charged tmRNA but not tmRNA-mediated proteolysis is essential for Neisseria gonorrhoeae viability.
CH HUANG, WC WOLFGANG, J WITHEY et al. EMBO J 2000;19:1098–1107

Chlamydia

Acute primary Chlamydia trachomatis infection in male adolescents after their first sexual contact.

Evaluation of patient-administered tampon specimens for Chlamydia trachomatis and Neisseria gonorrhoeae.

EL CIEMINS, CK KENT, J FLOOD, JD KLAUSNER. Sex Transm Dis 2000;27:165–7

Impact of switching laboratory tests on reported trends in Chlamydia trachomatis infections.

Detection of Chlamydia trachomatis in pregnant women by the Papanicolaou technique, enzyme immunoassay and polymerase chain reaction.

Multicenter evaluation of the AMPLICOR and automated COBAS AMPLICOR CT/NG tests for detection of Chlamydia trachomatis.

Chlamydial development is adversely affected by minor changes in amino acid supply, blood plasma amino acid levels and glucose deprivation.

Differential regulation of CD4 lymphocyte recruitment between the upper and lower regions of the genital tract during Chlamydia trachomatis infection.

T-cell epitopes in variable segments of Chlamydia trachomatis major outer membrane protein elicit serovarspecific immune responses in infected humans.

Candidiasis

Vaginal colonization by Candida in asymptomatic women with and without a history of recurrent vulvovaginal candidiasis.

Effects of reproductive hormones on experimental vaginal candidiasis.

Evaluation of the Oriclut-N dipslide for laboratory diagnosis of vaginal candidiasis.
P CARLSON, M RICHATTSION, J PAVONENS. J Clin Microbiol 2000;38:1063–76

Clonal and spontaneous origins of fluconazole resistance in Candida albicans.

Mechanisms of the proinflammatory response of endothelial cells to Candida albicans infection.

Bacterial vaginosis

Bacterial vaginosis.
B NIEVES. Anaerobe 1999;5:343–6

Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis.

Pre-term labor associated with bacterial vaginosis.
H CALDEIRA, B NIEVES, A QUINTANA. Anaerobe 1999;5:403–4
Trichomoniasis

Resistance of *Trichomonas vaginalis* to metronidazole: report of the first three cases from Finland and optimization of in vitro susceptibility testing under various oxygen concentrations.


Antigenicity of *Trichomonas vaginalis* heat-shock proteins in human infections.


Pelvic inflammatory disease

Pelvic inflammatory disease—an evidence-based approach to diagnosis.


Influence of human immunodeficiency virus infection on pelvic inflammatory disease.


Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing but still substantial.


Syphilis and other treponematoses

Unraveling the Tuskegee Study for untreated syphilis.


Nodular tertiary syphilis mimicking granuloma annulare.


Social network method for endemic foci of syphilis: a pilot project.


Geographic variation of HIV infection in childbearing women with syphilis in the United States.


HIV prevalence in patients with syphilis, United States.


From the CDC—syphilis elimination: history in the making—opening remarks.


From the CDC—syphilis elimination: history in the making—closing remarks.


Primary and secondary syphilis in the metropolitan area of Nashville and Davidson County, Tennessee—1996 to 1998 epidemic described.


Virulent *Treponema pallidum* lipoprotein and synthetic lipopeptides induce CCR5 on human monocytes and enhance their susceptibility to infection by human immunodeficiency virus type 1.


Hepatitis

International congress on viral hepatitis A and B: experience in education and prevention.

Vaccine 2000;18:Suppl 1 (whole issue)

The seroprevalence of hepatitis A and B in people testing positive for hepatitis C.


‘Silent killer’ or benign disease? The dilemma of hepatitis C virus outcomes.


Hepatitis C epidemiology: injecting new tools in the field.


45-Year follow-up of hepatitis C virus infection in healthy young adults.


Prevalence of hepatitis C virus in patients with hemophilia and their steady female sexual partners.


Are booster immunizations needed for lifelong hepatitis B immunity?


Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen.


Herpes

Herpes simplex type 2 infection in the developing world: is it time to address this disease?

L. Corey. *Sex Transm Dis* 2000;27:30–1

Genital herpes and public health: addressing a global problem.


Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.


Herpes simplex virus type 2 shedding in human immunodeficiency virus-negative men who have sex with men: frequency, patterns and risk factors.


Editorial response: Asymptomatic herpes simplex virus shedding and Russian roulette.


Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection.


Medical care expenditures for genital herpes in the United States.


Herpes simplex virus DNA in amniotic fluid without neonatal infection.


Herpes simplex virus infection of the uterine cervix—relationship with a cervical factor?


The herpesvirus proteases as targets for antiviral chemotherapy.


Monoclonal antibodies suitable for type-specific identification of herpes simplex viruses by a rapid culture assay.


Establishment of latent herpes simplex virus type 1 infection in resistant, sensitive and immunodeficient mouse strains.


Herpes simplex virus infection blocks events in the G1 phase of the cell cycle.

B. Song, J. Li, K.C. Yeh, D.M. Knipe. *Virology* 2000;267:326–34

Downloaded from http://sti.bmj.com/ on June 16, 2017 - Published by group.bmj.com
Human papillomavirus infection

Gynecological infections as risk determinants of subsequent cervical neoplasia.

Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids.

Human papillomavirus types 16 E6 and E7 contribute differently to carcinogenesis.
S Song, A Liem, JA Miller, PF Lambert. Virology 2000;267:141–50

Human papillomaviruses and DNA ploidy in anal condylomata acuminata.

HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain.


The human papillomavirus type 16 E5 protein modulates ERK1/2 and p38 MAP kinase activation by an EGFR-independent process in stressed human keratinocytes.
Nuclear matrix attachment regions of human papillomavirus type 16 repress or activate the E6 promoter, depending on the physical state of the viral DNA.


Repression of the integrated papillomavirus E6/E7 promoter is required for growth suppression of cervical cancer cells.


Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.


Adeno-associated virus major Rep78 protein disrupts binding of TATA-binding protein to the P97 promoter of human papillomavirus type 16.


Correlation of TGβ1 overexpression with down-regulation of proliferation-inducing molecules in HPV-11 transformed human tissue xenografts.


Human papillomavirus E7 proteins stimulate proliferation independently of their ability to associate with retinoblastoma protein.

S CALDEIRA, EM DEVILLIERS, M TOMMASINO. Oncogene 2000;19:821–6


The hinge of the human papillomavirus type 11 E2 protein contains major determinants for nuclear localization and nuclear matrix association.


The E7 oncogene of human papillomavirus type 16 interacts with F-actin in vitro and in vivo.


The human papillomavirus type 11 E1E4 protein is phosphorylated in genital epithelium.

JT BRYAN, A HAN, EH HIFE, DR BROWN. Virology 2000;268:430–9

Cervical cytology and colposcopy

Is it feasible for women to perform their own Pap smears? A research question in progress.


Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial.


Revisiting age effect of the Pap test on cervical cancer.

ND HOLMQUST. Am J Pub Health 2000;90:620–3


MK KOK, MK BOON, RH SCHREINEDER, LG KOSK. Hum Pathol 2000;31:23–8

Comparison of immediate and deferred colposcopy in a cervical screening program.


Quality control of cervical cytology in high-risk women: PAPNET system compared with manual rescreening.


Incidence of cervical squamous intraepithelial lesions in HIV-infected women.

TV ELLEBROECK, MA CHAISON, TJ BUSH et al. JAMA 2000;283:1031–7

Vaginal intraepithelial neoplasia and the Pap smear.

RM DAVILA, MC MIRANDA. Acta Cytol 2000;44:137–40

Effects of tamoxifen on cervicovaginal smears from patients with breast cancer.

MA ARASI, RB BARAKAT, PR SAIGO. Acta Cytol 2000;44:141–6

A comparison of the side effects of prilocaine with felypressin and lignocaine with adrenaline in large loop excision of the transformation zone of the cervix: results of a randomized trial.


Completeness of excision and follow-up cytology in patients treated with loop excision biopsy.


Expression of MNCA9 protein in Pan-pancicola smears containing atypical glandular cells of undetermined significance is a diagnostic biomarker of cervical dysplasia and neoplasia.

AY LIO, EJ STANBRIDGE. Cancer 2000;88:1108–21

Other sexually transmitted infections

Scabies and pediculosis.


Risk factors for human herpesvirus 8 seropositivity and seroconversion in a cohort of homosexual men.


Invited commentary: Determining specific sexual practices associated with human herpesvirus 8 transmission.


Duckers et al respond to “Sexual practices associated with HHV8 infection”.

NHTM DUCKERS, RA COUTINHO, J GOUDSMID. Am J Epidemiol 2000;151:230

Antibodies to human herpes virus type 8 (HHV8) in general population and in individuals at risk for sexually transmitted diseases in Western Sicily.


Prevalence and risk factors for human herpesvirus 8 infection in northern Cameroon.

G REZZA, O TCHANGMENA, MA ANDREONI et al. Sex Transm Dis 2000;27:168–74

Localization of Haemophilus ducreyi at the pustular stage of disease in the human model of infection.


Public health and social aspects

Evidence of declining STD prevalence in a South African mining community following a core-group intervention.

B STEEN, S VUYESTER, T MARSTON et al. Sex Transm Dis 2000;27:1–8
STD prevention: effectively reaching the core and a bridge population with a four-component intervention.
C J VANDAM, KK HOLMES. Sex Transm Dis 2000;27:9–11

A pragmatic intervention to promote condom use by female sex workers in Thailand.
N FORD, S KOETSAWANG. Bull WHO 1999;77:888–94

Factors associated with condom use for oral sex among female brothel-based sex workers in Singapore.
ML WONG, VW CHAN, D KOH, S WEE. Sex Transm Dis 2000;27:39–45

Effectiveness of an intervention promoting the female condom to patients at sexually transmitted disease clinics.

Comparisons of sexual behaviors, unprotected sex and substance use between two independent cohorts of gay and bisexual men.
KJP CRAIB, AC WEBER, PGA CORNELISSE et al. AIDS 2000;14:303–12

High prevalence of asymptomatic STDs in incarcerated minority male youth—a case for screening.
RP PACK, RJ DICLEMENTE, EW HOOK, MK OH. Sex Transm Dis 2000;27:175–7

Microbiology and immunology

Dermatology

Circumcision and genital dermatoses.

Vulvar intraepithelial neoplasia of the simplex (differentiated type): a clinicopathologic study including analysis of HPV and p53 expression.

Vulvovaginal soft tissue tumours: update and review.
MR NUCCI, CDM FLETCHER. Histopathol 2000;36:97–108

Protocol for the examination of specimens from patients with carcinomas and malignant melanomas of the vulva: a basis for checklists.
BJ WILKINSON. Arch Pathol Lab Med 2000;124:51–6

Mucocutaneous carcinoma arising in the glans penis.

Penile Kaposi's sarcoma preceded by chronic penile lymphedema.

Pathergy reaction in Behçet's disease: lack of correlation with mucocutaneous manifestations and systemic disease expression.

Case report: Artificial nodules of the penis—case report of an Indonesian man.

An unusual case of a metastatic lesion to the penis.
SS RAZI, FE GOTTINGER, RL GARCIA, KW LUI. J Urol 2000;163:908–9

Vaccines against sexually transmitted infections: promise and problems of the magic bullets for prevention and control.
GD ZIMET, RM MAYS, JD PORTENBERG. Sex Transm Dis 2000;27:49–52

Molecular epidemiologic approaches to urinary tract infection gene discovery in uropathogenic Escherichia coli.

Effect of chlorhexidine on genital microflora, Neisseria gonorrhoeae and Trichomonas vaginalis in vitro.
LK RAE, SI HILLIER. Sex Transm Dis 2000;27:74–8

Intravaginal practices, vaginal flora disturbances and acquisition of sexually transmitted diseases in Zimbabwean women.

Acceptability of formulations and application methods for vaginal microbicides among drug-involved women—results of product trials in three cities.

Miscellaneous

Is there a case for school-based screening for sexually transmitted diseases?
D HICKS. Lancet 2000;355:864

EL CIEMINS, CK KENT, J FLOOD, JD KLAUSNER. Sex Transm Dis 2000;27:154–8

Epidemiologic trends of sexually transmitted diseases in China.
X CHEN, XD GONG, GJ XUANG, GC ZHANG. Sex Transm Dis 2000;27:138–42

Editorial—sexually transmitted diseases in the People's Republic of China in 2K.
MS COHEN, G ONG, K FOX, GE HENDERSON. Sex Transm Dis 2000;27:143–5

Preventative intervention to reduce sexually transmitted infections: a field trial in the Royal Thai Army.

Etiology of sexually transmitted infections among street-based female sex workers in Dhaka, Bangladesh.

Prevalence of serum antibodies against bloodborne and sexually transmitted agents in selected groups in Somalia.
YA NUR, J GROEN, AM ELMI et al. Epidemiol Infect 2000;124:137–42

Recurrent urinary tract infections in postmenopausal women.

Women's sexual health after childbirth.

New policy on circumcision—cause for concern.

Letters, Book reviews, Notices, Correction, Current publications

229
Interleukin 1 receptor antagonist gene polymorphism in women with vulvar vestibulitis.

Sexual behaviour, STDs and risks for prostate cancer.

Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study.

Recurrent epididymo-orchitis in patients with Behçet’s disease.

Hypertrophy of labia minora: experience with 163 reductions.

Would women trust their partners to use a male pill?
HIV associated cytomegalovirus retinitis in Melbourne, Australia

C L Cherry, A M Mijch, J F Hoy, A J H Hall, M E Hellard, M Bryant, B DeGraaff and C K Fairley

Sex Transm Infect 2000 76: 221
doi: 10.1136/sti.76.3.221-a

Updated information and services can be found at:
http://sti.bmj.com/content/76/3/221.2

These include:

References
This article cites 2 articles, 0 of which you can access for free at:
http://sti.bmj.com/content/76/3/221.2#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/